A phase II, multi-centre, open label, randomised trial.~The trial will assess the delivery, response rate, treatment compliance, efficacy and safety of encorafenib and binimetinib compared to standard adjuvant therapy in patients with BRAFV600 mutant clinically detected AJCC stage III(B/C/D) or oligometastatic stage IV Melanoma.
A two-arm, randomised trial investigating the response of encorafenib and binimetinib compared to standard adjuvant therapy.